Cargando…
Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HC...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235710/ https://www.ncbi.nlm.nih.gov/pubmed/32260271 http://dx.doi.org/10.3390/biomedicines8040074 |
_version_ | 1783536017640259584 |
---|---|
author | Sugiura, Ayumi Joshita, Satoru Yamashita, Yuki Yamazaki, Tomoo Fujimori, Naoyuki Kimura, Takefumi Matsumoto, Akihiro Wada, Shuichi Mori, Hiromitsu Shibata, Soichiro Yoshizawa, Kaname Morita, Susumu Furuta, Kiyoshi Kamijo, Atsushi Iijima, Akihiro Kako, Satoko Maruyama, Atsushi Kobayashi, Masakazu Komatsu, Michiharu Matsumura, Makiko Miyabayashi, Chiharu Ichijo, Tetsuya Takeuchi, Aki Koike, Yuriko Gibo, Yukio Tsukadaira, Toshihisa Inada, Hiroyuki Nakano, Yoshiyuki Usuda, Seiichi Kiyosawa, Kendo Tanaka, Eiji Umemura, Takeji |
author_facet | Sugiura, Ayumi Joshita, Satoru Yamashita, Yuki Yamazaki, Tomoo Fujimori, Naoyuki Kimura, Takefumi Matsumoto, Akihiro Wada, Shuichi Mori, Hiromitsu Shibata, Soichiro Yoshizawa, Kaname Morita, Susumu Furuta, Kiyoshi Kamijo, Atsushi Iijima, Akihiro Kako, Satoko Maruyama, Atsushi Kobayashi, Masakazu Komatsu, Michiharu Matsumura, Makiko Miyabayashi, Chiharu Ichijo, Tetsuya Takeuchi, Aki Koike, Yuriko Gibo, Yukio Tsukadaira, Toshihisa Inada, Hiroyuki Nakano, Yoshiyuki Usuda, Seiichi Kiyosawa, Kendo Tanaka, Eiji Umemura, Takeji |
author_sort | Sugiura, Ayumi |
collection | PubMed |
description | Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HCV patients (n = 182) were compared for clinical features and outcomes between first treatment (n = 159) and retreatment (n = 23) G/P groups. Overall, 77 patients (42.3%) were male, the median age was 68 years, and 86/66/1/4 cases had genotype 1/2/1 + 2/3, respectively. An SVR was achieved in 97.8% (178/182) of cases by intention-to-treat analysis and 99.4% (178/179) of cases by per-protocol analysis. There were no remarkable differences between the first treatment and retreatment groups for male (42.8% vs. 39.1%, p = 0.70), median age (68 vs. 68 years, p = 0.36), prior hepatocellular carcinoma (5.8% vs. 8.7%, p = 0.59), or the fibrosis markers AST-to-platelet ratio index (APRI) (0.5 vs. 0.5, p = 0.80) and fibrosis-4 (FIB-4) index (2.2 vs. 2.6, p = 0.59). The retreatment group had a significantly more frequent history of interferon treatment (12.3% vs. 52.2%, p < 0.01) and the Y93H mutation (25.0% vs. 64.7%, p = 0.02). The number of retreatment patients who had experienced 3, 2, and 1 DAA treatment failures was 1, 3, and 19, respectively, all of whom ultimately achieved an SVR by G/P treatment. In conclusion, G/P was effective and safe for both HCV first treatment and retreatment cases despite the retreatment group having specific resistance mutations for other prior DAAs. As G/P treatment failure has been reported for P32 deletions, clinicians should consider resistance mutations during DAA selection. |
format | Online Article Text |
id | pubmed-7235710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72357102020-05-22 Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases Sugiura, Ayumi Joshita, Satoru Yamashita, Yuki Yamazaki, Tomoo Fujimori, Naoyuki Kimura, Takefumi Matsumoto, Akihiro Wada, Shuichi Mori, Hiromitsu Shibata, Soichiro Yoshizawa, Kaname Morita, Susumu Furuta, Kiyoshi Kamijo, Atsushi Iijima, Akihiro Kako, Satoko Maruyama, Atsushi Kobayashi, Masakazu Komatsu, Michiharu Matsumura, Makiko Miyabayashi, Chiharu Ichijo, Tetsuya Takeuchi, Aki Koike, Yuriko Gibo, Yukio Tsukadaira, Toshihisa Inada, Hiroyuki Nakano, Yoshiyuki Usuda, Seiichi Kiyosawa, Kendo Tanaka, Eiji Umemura, Takeji Biomedicines Article Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HCV patients (n = 182) were compared for clinical features and outcomes between first treatment (n = 159) and retreatment (n = 23) G/P groups. Overall, 77 patients (42.3%) were male, the median age was 68 years, and 86/66/1/4 cases had genotype 1/2/1 + 2/3, respectively. An SVR was achieved in 97.8% (178/182) of cases by intention-to-treat analysis and 99.4% (178/179) of cases by per-protocol analysis. There were no remarkable differences between the first treatment and retreatment groups for male (42.8% vs. 39.1%, p = 0.70), median age (68 vs. 68 years, p = 0.36), prior hepatocellular carcinoma (5.8% vs. 8.7%, p = 0.59), or the fibrosis markers AST-to-platelet ratio index (APRI) (0.5 vs. 0.5, p = 0.80) and fibrosis-4 (FIB-4) index (2.2 vs. 2.6, p = 0.59). The retreatment group had a significantly more frequent history of interferon treatment (12.3% vs. 52.2%, p < 0.01) and the Y93H mutation (25.0% vs. 64.7%, p = 0.02). The number of retreatment patients who had experienced 3, 2, and 1 DAA treatment failures was 1, 3, and 19, respectively, all of whom ultimately achieved an SVR by G/P treatment. In conclusion, G/P was effective and safe for both HCV first treatment and retreatment cases despite the retreatment group having specific resistance mutations for other prior DAAs. As G/P treatment failure has been reported for P32 deletions, clinicians should consider resistance mutations during DAA selection. MDPI 2020-04-03 /pmc/articles/PMC7235710/ /pubmed/32260271 http://dx.doi.org/10.3390/biomedicines8040074 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sugiura, Ayumi Joshita, Satoru Yamashita, Yuki Yamazaki, Tomoo Fujimori, Naoyuki Kimura, Takefumi Matsumoto, Akihiro Wada, Shuichi Mori, Hiromitsu Shibata, Soichiro Yoshizawa, Kaname Morita, Susumu Furuta, Kiyoshi Kamijo, Atsushi Iijima, Akihiro Kako, Satoko Maruyama, Atsushi Kobayashi, Masakazu Komatsu, Michiharu Matsumura, Makiko Miyabayashi, Chiharu Ichijo, Tetsuya Takeuchi, Aki Koike, Yuriko Gibo, Yukio Tsukadaira, Toshihisa Inada, Hiroyuki Nakano, Yoshiyuki Usuda, Seiichi Kiyosawa, Kendo Tanaka, Eiji Umemura, Takeji Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases |
title | Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases |
title_full | Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases |
title_fullStr | Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases |
title_full_unstemmed | Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases |
title_short | Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases |
title_sort | effectiveness of glecaprevir/pibrentasvir for hepatitis c: real-world experience and clinical features of retreatment cases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235710/ https://www.ncbi.nlm.nih.gov/pubmed/32260271 http://dx.doi.org/10.3390/biomedicines8040074 |
work_keys_str_mv | AT sugiuraayumi effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT joshitasatoru effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT yamashitayuki effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT yamazakitomoo effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT fujimorinaoyuki effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT kimuratakefumi effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT matsumotoakihiro effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT wadashuichi effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT morihiromitsu effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT shibatasoichiro effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT yoshizawakaname effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT moritasusumu effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT furutakiyoshi effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT kamijoatsushi effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT iijimaakihiro effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT kakosatoko effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT maruyamaatsushi effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT kobayashimasakazu effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT komatsumichiharu effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT matsumuramakiko effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT miyabayashichiharu effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT ichijotetsuya effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT takeuchiaki effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT koikeyuriko effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT giboyukio effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT tsukadairatoshihisa effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT inadahiroyuki effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT nakanoyoshiyuki effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT usudaseiichi effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT kiyosawakendo effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT tanakaeiji effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases AT umemuratakeji effectivenessofglecaprevirpibrentasvirforhepatitiscrealworldexperienceandclinicalfeaturesofretreatmentcases |